Cargando…
Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future
Coronavirus disease 2019 (COVID-19) has posed unprecedented challenges for nations worldwide, among which medication shortages can cause a devastatingly negative impact on global health. Using Taiwan as an example, this report describes the sources of potential medication shortages, discusses the pr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Pharmacists Association®. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439991/ https://www.ncbi.nlm.nih.gov/pubmed/32919923 http://dx.doi.org/10.1016/j.japh.2020.08.029 |
_version_ | 1783573077866577920 |
---|---|
author | Kuo, Shihchen Ou, Huang-Tz Wang, C. Jason |
author_facet | Kuo, Shihchen Ou, Huang-Tz Wang, C. Jason |
author_sort | Kuo, Shihchen |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) has posed unprecedented challenges for nations worldwide, among which medication shortages can cause a devastatingly negative impact on global health. Using Taiwan as an example, this report describes the sources of potential medication shortages, discusses the preparedness and contingency strategies to address medication shortages, and outlines the evidence-based recommendations on ensuring a stable medication supply and improving the quality and security of medicines. Many drug shortages have focused on shortfalls of overseas manufacturing, but the effect of the COVID-19 crisis on misallocation of medications within the nation’s internal supply chains is also a great concern. A wide range of stakeholders are involved in pharmaceutical supply chains, including government regulators, health care insurers, pharmaceutical companies, frontline physicians and pharmacists, patients and families, professional and patient associations or unions, and even individuals who acquire medications from abroad. Collaborative inputs and efforts from all these interdependent stakeholders are critical for establishing transparent preparedness and contingency plans to address drug shortages affected by disruptions of overseas manufacturing or stockouts in pharmacies owing to medication misallocation. Strategies have been documented and recommended in Taiwan and the United States to mitigate drug shortages and ensure the long-term quality and security of medicines. Barriers to accessing medicines are nothing new, but the COVID-19 pandemic poses urgent and even novel challenges to the stability and integrity of medication supply, which urges for a need to reconsider and reinforce effective management strategies for pharmaceuticals. Active management, transparent information, and timely communications are essential to ensure a stable supply of key therapeutic medications, especially during a pandemic. |
format | Online Article Text |
id | pubmed-7439991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Pharmacists Association®. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74399912020-08-21 Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future Kuo, Shihchen Ou, Huang-Tz Wang, C. Jason J Am Pharm Assoc (2003) Science and Practice Coronavirus disease 2019 (COVID-19) has posed unprecedented challenges for nations worldwide, among which medication shortages can cause a devastatingly negative impact on global health. Using Taiwan as an example, this report describes the sources of potential medication shortages, discusses the preparedness and contingency strategies to address medication shortages, and outlines the evidence-based recommendations on ensuring a stable medication supply and improving the quality and security of medicines. Many drug shortages have focused on shortfalls of overseas manufacturing, but the effect of the COVID-19 crisis on misallocation of medications within the nation’s internal supply chains is also a great concern. A wide range of stakeholders are involved in pharmaceutical supply chains, including government regulators, health care insurers, pharmaceutical companies, frontline physicians and pharmacists, patients and families, professional and patient associations or unions, and even individuals who acquire medications from abroad. Collaborative inputs and efforts from all these interdependent stakeholders are critical for establishing transparent preparedness and contingency plans to address drug shortages affected by disruptions of overseas manufacturing or stockouts in pharmacies owing to medication misallocation. Strategies have been documented and recommended in Taiwan and the United States to mitigate drug shortages and ensure the long-term quality and security of medicines. Barriers to accessing medicines are nothing new, but the COVID-19 pandemic poses urgent and even novel challenges to the stability and integrity of medication supply, which urges for a need to reconsider and reinforce effective management strategies for pharmaceuticals. Active management, transparent information, and timely communications are essential to ensure a stable supply of key therapeutic medications, especially during a pandemic. American Pharmacists Association®. Published by Elsevier Inc. 2021 2020-08-20 /pmc/articles/PMC7439991/ /pubmed/32919923 http://dx.doi.org/10.1016/j.japh.2020.08.029 Text en © 2021 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Science and Practice Kuo, Shihchen Ou, Huang-Tz Wang, C. Jason Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future |
title | Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future |
title_full | Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future |
title_fullStr | Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future |
title_full_unstemmed | Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future |
title_short | Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the future |
title_sort | managing medication supply chains: lessons learned from taiwan during the covid-19 pandemic and preparedness planning for the future |
topic | Science and Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439991/ https://www.ncbi.nlm.nih.gov/pubmed/32919923 http://dx.doi.org/10.1016/j.japh.2020.08.029 |
work_keys_str_mv | AT kuoshihchen managingmedicationsupplychainslessonslearnedfromtaiwanduringthecovid19pandemicandpreparednessplanningforthefuture AT ouhuangtz managingmedicationsupplychainslessonslearnedfromtaiwanduringthecovid19pandemicandpreparednessplanningforthefuture AT wangcjason managingmedicationsupplychainslessonslearnedfromtaiwanduringthecovid19pandemicandpreparednessplanningforthefuture |